Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study

Author:

Geist Mary L.,Radick Andrea C.,Tsui Judith I.,Blalock Kendra L.,Adwell Addy,Tamru Elsabeth,Connolly Nancy C.,James Jocelyn R.ORCID

Abstract

Abstract Background This study examined associations between receipt of hepatitis C (HCV) treatment and retention in office-based opioid treatment (OBOT) care. Methods We conducted a retrospective cohort study of HCV-infected patients who initiated OBOT treatment between December 2015 and March 2021 to characterize HCV treatment and assess associations with OBOT retention. HCV treatment was characterized as no treatment, early treatment (< 100 days since OBOT initiation) or late treatment (≥ 100 days). We evaluated associations between HCV treatment and cumulative days in OBOT. A secondary analysis using Cox Proportional Hazards regression was done to determine the rate of discharge over time when comparing those who did versus did not receive HCV treatment as a time-varying covariate. We also analyzed a subset of patients retained at least 100 days in OBOT care and evaluated whether HCV treatment during that period was associated with OBOT retention beyond 100 days. Results Of 191 HCV-infected OBOT patients, 30% initiated HCV treatment, of whom 31% received early treatment and 69% received late treatment. Median cumulative duration in OBOT was greater among those who received HCV treatment (any: 398 days, early: 284 days and late: 430 days) when compared to those who did not receive treatment (90 days). Compared to no HCV treatment, there were 83% (95% CI: 33–152%, P < 0.001), 95% (95% CI: 28%-197%, p = 0.002 and 77% (95% CI: 25–153%, p = 0.002) more cumulative days in OBOT for any, early and late HCV treatment, respectively. HCV treatment was associated with a lower relative hazard for discharge/drop-out, although results did not meet statistical significance (aHR = 0.59;95% CI: 0.34–1.00; p = 0.052). Among the subset of 84 patients retained in OBOT at least 100 days, 18 received HCV treatment during that period. Compared to those who did not receive treatment within the first 100 days, those who received treatment had 57% (95% CI: -3%-152%, p = 0.065) more subsequent days in OBOT. Conclusions A minority of HCV-infected patients received HCV treatment after initiating OBOT treatment, but those who did had better retention. Further efforts are needed to facilitate rapid HCV treatment and evaluate whether early HCV treatment improves OBOT engagement.

Funder

National Institute on Drug Abuse

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Reference34 articles.

1. Centers for Disease Control and Prevention. Viral hepatitis surveillance report 2018—hepatitis C. Updated August 28, 2020. https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepC.htm. Accessed 4 Feb 2022.

2. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39-45. https://doi.org/10.1093/cid/cit296.

3. Committee on a National Strategy for the Elimination of Hepatitis B, Board on Population H, Public Health P, et al. In: Buckley GJ, Strom BL, eds. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. National Academies Press (US). Copyright 2016 by the National Academy of Sciences. All rights reserved; 2016.

4. Dore GJ, Martinello M, Alavi M, Grebely J. Global elimination of hepatitis C virus by 2030: why not? Nat Med. 2020;26(2):157–60. https://doi.org/10.1038/s41591-019-0706-x.

5. Palmateer NE, McAuley A, Dillon JF, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction. 2021;116(10):2893–907. https://doi.org/10.1111/add.15459.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Cost effectiveness of hepatitis C direct acting agents;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3